Email this article CHARACTERIZATION OF HUMAN PAPILLOMAVIRUS VACCINES: THE WORLD EXPERIENCE
- Authors: Gorenkov D.V.1, Nikitina T.N.1, Volgin A.R.1, Klimov V.I.1
-
Affiliations:
- The Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
- Issue: Vol 22, No 4 (2019)
- Pages: 1454-1456
- Section: ORIGINAL ARTICLES
- Submitted: 19.10.2020
- Accepted: 19.10.2020
- Published: 20.12.2019
- URL: https://rusimmun.ru/jour/article/view/546
- DOI: https://doi.org/10.31857/S102872210007055-5
- ID: 546
Cite item
Full Text
Abstract
Persistence of high-risk human papillomavirus (HPV) genotypes is the leading cause of cervical cancer, as well as anogenital and oropharyngeal cancers. This article focuses on analysis of the global use of the licensed HPV vaccines, given the introduction of HPV vaccination into national immunization programs of many countries. All vaccines are safe, immunogenic and effective in population usage, with the most frequent adverse event being injection-site reactions.
About the authors
D. V. Gorenkov
The Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Author for correspondence.
Email: fake@neicon.ru
Category 1 Expert,
Moscow
Russian FederationT. N. Nikitina
The Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Email: fake@neicon.ru
PhD, Main Expert,
Moscow
Russian FederationA. R. Volgin
The Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Email: fake@neicon.ru
PhD, Deputy Director of Centre for Evaluation and Control of MIBPs,
Moscow
Russian FederationV. I. Klimov
The Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Email: fake@neicon.ru
PhD, Deputy Director of Centre for Planning and Coordination of Scientific Activities,
Moscow
Russian Federation
References
- Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piсeros M., Znaor A., Soerjomataram I., Bray F. (2018). Global Cancer Observatory: Cancer Today. Lyon, France: IARC. https://gco.iarc.fr/today
- Lin S. W., Ghosh A., Porras C., Markt S. C., Rodriguez A. C., Schiff man M., Wacholder S., Kemp T. J., Pinto L. A., Gonzalez P., Wentzensen N., Esser M. T., Matys K., Meuree A., Quint W., van Doorn L. J., Herrero R., Hildesheim A., Safaeian M. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS One. 2013;8(1): e53067. https://doi.org/10.1371/journal.pone.0053067
- Brotherton J. M. L, Bloem P. N., Population-based HPV vaccination programmes are safe and eff ective: 2017 update and the impetus for…, Best Practice & Research Clinical Obstetrics and Gynaecology (2017), http://dx.doi.org/10.1016/j.bpobgyn.2017.08.010
- Chaturvedi A. K., Graubard B. I., Broutian T., Pickard R. K. L, Tong Z. Y., Xiao W., Kahle L., Gillison M. L. Eff ect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States. J Clin Oncol. 2018;36(3):262. Epub 2017 Nov 28.
- Phillips A., Patel C., Pillsbury A. et al. Safety of Human Papillomavirus Vaccines: An Updated Review. Drug Saf. 2018;41:329. https://doi.org/10.1007/s40264-017-0625-z
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).